NeuroSense Therapeutics (Nasdaq:NRSN) - Hisse Senedi Fiyatı, Haberler ve Analizler

NRSN Stoklara Genel Bakış

NRSN temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Negatif hissedar öz sermayesi

Son 3 ayda dalgalı hisse senedi fiyatı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 2 daha fazla risk

NeuroSense Therapeutics Ltd. Rakipler

Enlivex Therapeutics

NasdaqCM:ENLV

US$19.9m

Finch Therapeutics Group

OTCPK:FNCH

US$19.3m

MEI Pharma

NasdaqCM:MEIP

US$18.5m

Synlogic

NasdaqCM:SYBX

US$16.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti NeuroSense Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.90
52 Haftanın En Yüksek Seviyesi	US$2.33
52 Haftanın En Düşük Seviyesi	US$0.51
Beta	1.57
11 Aylık Değişim	-29.13%
3 Aylık Değişim	10.84%
1 Yıllık Değişim	40.17%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-77.72%

Son Haberler & Güncellemeler

Recent updates

We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Jul 06

NeuroSense climbs 66% after early data supporting Alzheimer’s candidate

Jun 30

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

Mar 31

NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

Mar 22

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

Dec 22

Hissedar Getirileri

	NRSN	US Biotechs	US Pazar
7D	-26.8%	2.5%	2.2%
1Y	40.2%	16.1%	31.6%

Getiri vs. Endüstri: NRSN geçen yıl % 16.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: NRSN geçen yıl % 31.6 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is NRSN's price volatile compared to industry and market?
NRSN volatility
NRSN Average Weekly Movement	12.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: NRSN hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: NRSN 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2017	18	Alon Ben-Noon	www.neurosense-tx.com

Klinik aşamada bir biyoteknoloji şirketi olan NeuroSense Therapeutics Ltd., Amerika Birleşik Devletleri'nde ve uluslararası alanda zayıflatıcı nörodejeneratif hastalıklardan muzdarip hastalar için tedaviler keşfetmeye ve geliştirmeye odaklanmaktadır. Şirketin öncü ürünü, siprofloksasin ve selekoksibin sabit doz kombinasyonunun uzatılmış salımlı oral formülasyonu olan PrimeC'dir ve şu anda amiyotrofik lateral skleroz tedavisi için Faz 2b / 3 klinik deneyleri devam etmektedir ve Alzheimer tedavisi için Faz 2 klinik deneylerini tamamlamıştır ve Parkinson hastalığının tedavisi için klinik öncesi çalışmalar devam etmektedir. Klinik öncesi çalışmaları arasında Parkinson hastalığının tedavisi için StabiliC ve Alzheimer hastalığının tedavisi için CogniC yer almaktadır.

NeuroSense Therapeutics Ltd. Temel Bilgiler Özeti

NeuroSense Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NRSN temel i̇stati̇sti̇kler
Piyasa değeri	US$17.52m
Kazançlar(TTM)	-US$9.80m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-1.8x

F/K Oranı

NRSN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NRSN gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$9.80m
Kazançlar	-US$9.80m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.50
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

NRSN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NRSN Stoklara Genel Bakış

Risk Analizi

NeuroSense Therapeutics Ltd. Rakipler

NasdaqCM:ENLV

US$19.9m

OTCPK:FNCH

US$19.3m

NasdaqCM:MEIP

US$18.5m

NasdaqCM:SYBX

US$16.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

NeuroSense Therapeutics Ltd. Advances Plans for Early Commercialization of ALS Treatment in Canada

Neurosense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

New major risk - Share price stability

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Ltd. has filed a Follow-on Equity Offering in the amount of $2.524437 million.

Recent updates

NeuroSense Therapeutics Ltd. Advances Plans for Early Commercialization of ALS Treatment in Canada

Neurosense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

New major risk - Share price stability

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Ltd. has filed a Follow-on Equity Offering in the amount of $2.524437 million.

NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding

NeuroSense Therapeutics Ltd. Announces Positive Biomarker Data from ALS Phase 2B Clinical Trial

NeuroSense Therapeutics Ltd. Announces Additional Positive Results from its 12-Month PARADIGM Phase 2b Study of PrimeC in ALS Patients

NeuroSense Therapeutics Ltd. Reports Statistically Significant Results from the 12-Month Paradigm Study Evaluating PrimeC in People Living with Amyotrophic Lateral Sclerosis

New major risk - Shareholder dilution

NeuroSense Therapeutics Ltd., Annual General Meeting, Jun 27, 2024

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

NeuroSense Therapeutics Ltd. announced that it expects to receive $4.47 million in funding

NeuroSense Therapeutics (NASDAQ:NRSN) Will Have To Spend Its Cash Wisely

Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Neurosense Therapeutics Ltd. Reports Additional Positive Efficacy Data from Further Evaluation of Its Phase 2B Als Trial

Can NeuroSense Therapeutics (NASDAQ:NRSN) Afford To Invest In Growth?

NeuroSense Therapeutics Ltd.'s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

New major risk - Share price stability

New major risk - Revenue and earnings growth

Neurosense Receives U.S. Fda Confirmation of Cmc Strategy for Primec in Preparation for Pivotal Phase 3 in Als and Commercial Readiness

Neurosense Therapeutics Ltd. Announces Results of Non-Sponsored in Vitro Study of PrimeC in Amyotrophic Lateral Sclerosis

European Medicines Agency Grants the Small and Medium-Sized Enterprise Status of Neurosense Therapeutics Ltd

New major risk - Negative shareholders equity

New minor risk - Shareholder dilution

High number of new and inexperienced directors

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

NeuroSense Therapeutics Ltd. Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial

NeuroSense Therapeutics Ltd. Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study

NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study

Will NeuroSense Therapeutics (NASDAQ:NRSN) Spend Its Cash Wisely?

NeuroSense Therapeutics Ltd. Receives Regulatory Approval to Commence Patient Enrollment in Italy for Its Phase 2B Trial in Als

Neurosense Receives FDA Clearance of IND for Its ALS Phase 2b Study

Less than half of directors are independent

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

Neurosense Therapeutics Ltd. Announces Positive Primec Toxicology Data Supportive of Current Phase IIb Paradigm Als Clinical Trial

NeuroSense Therapeutics GAAP EPS of -$0.55

NeuroSense Therapeutics Ltd. Reports Strong Patient Enrollment in Its Phase IIb PARADIGM Trial for Its Lead Drug Candidate PrimeC for the Treatment of ALS

NeuroSense Joins Everything ALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

We're Not Very Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

Neurosense Therapeutics Ltd. Reports Completion of the "In-Life" Phase of Its 90-Day Glp Toxicology Study Successfully

NeuroSense climbs 66% after early data supporting Alzheimer’s candidate

NeuroSense Therapeutics Ltd. Reports Positive Results from Stage III ALS Biomarker Study

NeuroSense Therapeutics Ltd. Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

NeuroSense Therapeutics Ltd., Annual General Meeting, Jun 21, 2022

Less than half of directors are independent

NeuroSense Therapeutics Commences Enrollment and Dosing in its Pharmacokinetic Study of PrimeC for ALS

Is NeuroSense Stock A Buy, Sell, Or Hold After Jumping Up In March?

NeuroSense Therapeutics (NASDAQ:NRSN) Is In A Good Position To Deliver On Growth Plans

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

NeuroSense Therapeutics Ltd. has completed an IPO in the amount of $12 million.

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

NeuroSense Therapeutics Ltd. Temel Bilgiler Özeti

0.0x

-1.8x